The Clinical application for Pax1 methylation in the malignant tendency of cervical lesions

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025114

Enrollment

Unknown

Registered

2019-08-12

Start date

2020-01-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical lesions

Interventions

Gold Standard:Pathology results

Index test:Pax1 methylation

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Cervical screening popuulation; cervical neoplasia population; postoperative treatment of cervical lesions in population.

Exclusion criteria

Exclusion criteria: Population participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
the degree of Pax1 methylation;the high risk of HPV screening;SEN, SPE, ACC, AUC of ROC;	—

Secondary

Measure	Time frame
colposcope;	—

Countries

China

Contacts

Public ContactLin Zhu

The Second Hospital of Shandong University

zl-emtf@163.com+86 17660082288

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026